Volume | 730,320 |
|
|||||
News | - | ||||||
Day High | 2.40 | Low High |
|||||
Day Low | 2.25 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Cardiol Therapeutics Inc | CRDL | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.27 | 2.25 | 2.40 | 2.35 | 2.23 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
2,870 | 730,320 | US$ 2.34 | US$ 1,709,125 | - | 0.63 - 2.41 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:11:56 | 1 | US$ 2.39 | USD |
Cardiol Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
208.36M | 65.11M | - | 0 | -28.13M | -0.43 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Cardiol Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRDL Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.40 | 2.40 | 2.12 | 2.19 | 257,963 | -0.05 | -2.08% |
1 Month | 1.81 | 2.41 | 1.74 | 2.12 | 369,840 | 0.54 | 29.83% |
3 Months | 2.15 | 2.41 | 1.35 | 1.90 | 319,036 | 0.20 | 9.30% |
6 Months | 0.87 | 2.41 | 0.7912 | 1.61 | 305,514 | 1.48 | 170.11% |
1 Year | 0.69 | 2.41 | 0.63 | 1.33 | 255,669 | 1.66 | 240.58% |
3 Years | 2.63 | 4.96 | 0.45 | 2.03 | 307,424 | -0.28 | -10.65% |
5 Years | 2.63 | 4.96 | 0.45 | 2.03 | 307,424 | -0.28 | -10.65% |
Cardiol Therapeutics Description
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. |